Spina bifida and anencephaly: fewer patients, more problems Anencephaly and spina bifida aperta occur when the neural tube fails to develop normally and are the most striking of the common malformations. Ever since the pioneering studies of Record and McKeown' 2 it has been evident that the birth prevalence of these defects-the number of affected infants born, dead or alive, expressed as a proportion of all live births and stillbirths-varies widely and that these variations are broadly similar for the two defects. 4 Some of the variations-for example, those observed with sex, family relationship, and colour-may be due to genetic factors. Othersnotably differences in liability between first born and other children of the same families, and trends over space and time in populations of apparently similar genetic composition-are probably related to the prenatal environment.
These genetic and environmental influences may produce their effects by affecting either the proportion of embryos which become malformed (incidence) or the proportion of malformed embryos which result in spontaneous abortion. Most of the effects that have been studied appear to reflect differences in incidence, though the available evidence is limited.4 Accordingly it is widely believed that many genes and environmental factors affect development of the neural tube. In each individual embryo it is suggested that these effects add up to a score, and that neural tube defects arise in those whose score exceeds a critical threshold. 10 and Australia,"1 12 though in these countries the reduction has been less striking than in England and Wales. The reduction has been greater for anencephaly than for spina bifida except in parts of the United States. " BRITISH MEDICAL JOURNAL 1983. All reproduction rights reserved.
One piece of evidence for screening programmes being the main sources of this decline in prevalence is a report that in the Irish Republic, where there is no antenatal screening programme, the decline has been negligible.13 On the other hand, the increasing number of terminations of pregnancy reported from Britain and Australia is insufficientto account for more than a small part of the decline in these countries,8 121415 while in the United States the decline started well before 1970 in the absence of screening.9 1016 In the Netherlands the prevalence of anencephaly has fallen fairly consistently since the 1950s.'7 In more recent years periods of stable prevalence in Britain and the north eastern United States have been preceded as well as followed by substantial changes-for example, a rise in the prevalence of anencephaly and spina bifida during the early 1950s and a fall during the next decade in England.15 These earlier trends also suggest that antenatal screening is not the only factor behind the recent decline-in which case this decline will have reduced the cost effectiveness of screening.
On the second point, the anticonvulsant drug sodium valproate is teratogenic in rodents.'8 In a recent report from France spina bifida was described in three tenths of 30 malformed children born between 1976 and 1982 with a history of exposure to sodium valproate in the first trimester of pregnancy. This figure was nearly 15 times the corresponding number for children with no exposure to the drug. Similar inquiries elsewhere in Europe and America yielded comparable findings in one population but no cases of spina bifida after exposure to the drug in six others, data which fail to clarify the problem, since these populations did not seem to have used much sodium valproate.19 In yet-another group of children with congenital malformations born to mothers taking sodium valproate, nine out of 39 had spina bifida. 20 Both reports suggest that either the diagnosis of spina bifida has been sought and confirmed more assiduously than other malformations in children exposed to the drug or that the proportion of malformed children who have spina bifida is indeed higher after exposure to sodium valproate. With other anticonvulsant drugs, by contrast, the proportion of malformed children with oral clefts and congenital heart disease is increased. 21 But it is not the frequency of spina bifida among malformed children but its frequency among all children after exposure to sodium valproate that most needs to be explored. BRITISH MEDICAL JOURNAL VOLUmE 286 28 mAY 1983 For this the published data are insufficient, and we must await studies in which normal as well as malformed births to takers and non-takers of sodium valproate are fully represented.
Meanwhile, women who have taken the drug in early pregnancy should perhaps be offered an amniocentesis to check the concentration of ax-fetoprotein in the amniotic fluid. The third and most contentious question concerns the hypothesis that vitamin supplements during pregnancy prevent defects of the neural tube. Other publications22 23 have reviewed the observations which support this hypothesis: evidence from studies in animals, experience with the use of drugs which are antagonists of folic acid, seasonal and social class variations in prevalence and nutrition, correlations between the outcome of pregnancy and concentrations of vitamins in the blood in early pregnancy, and, finally, the apparent success of two clinical trials of vitamin supplements given in the periconceptional period to women who had previously produced affected children. Even these trials, however, do not prove conclusively that vitamin supplements prevent defects of the neural tube. In the first trial, a double blind comparison of folic acid and a placebo, the difference in the outcome of pregnancy was not statistically significant.24 The second study, using a combination of folate and other vitamins, was not a randomised controlled trial and compared women who accepted vitamins before conception with those who either declined them or who were already pregnant.25 26 This trial is intended to show whether vitamin supplements can reduce the recurrence rates of defects of the neural tube to the extent suggested by the second trial (about sixfold). It will succeed, however, only if there is no great decline in "natural" recurrence rates and if the intended number of participants-at least 2000-can be recruited and then restrained from taking other vitamin preparations. It will be surprising if all these provisions are satisfied. With the current decline in prevalence we may expect recurrence rates to fall, since the two tend to vary concordantly.4 28 29 Even more important, any normal mother of an affected child who is told (as potential participants must be) that vitamin supplementation may possibly prevent recurrence and that entering the trial may mean forgoing such treatment will surely decline to participate. Her family doctor will probably back this decision, especially since the advice recently proffered in the BMJ was that "folate should be given to any woman with a ... history of a child with spina bifida or anencephaly" who wishes to conceive.30 A more practicable and ethical way to reassess whether or not vitamin supplements reduce recurrence rates might be to look at how these rates have changed in the recent past. In periods and places in which vitamin supplements have been widely used one would expect to find a lower overall recurrence rate than elsewhere if supplementation were really effective, but not if the differences observed between supplemented and unsupplemented pregnancies were due only to self selection.
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Pregnancy in patients with prosthetic heart valves Patients who have had palliative or corrective cardiac surgery for congenital or acquired heart disease are being seen increasingly often as candidates for antenatal cardiac care. Cardiac surgery is usually not curative and each such patient requires individual assessment. The chances of success depend on their haemodynamic state, the effects of pregnancy on this and on fetal development, the likelihood of thromboembolic or infective complications, the possible effects on the child of
